Ignite Creation Date:
2024-05-06 @ 3:25 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02289222
Status:
TERMINATED
Last Update Posted:
2019-11-05
First Post:
2014-10-17
Brief Title:
1454GCC Anti-PD-1 MK-3475 and IMiD Pomalidomide Combination Immunotherapy in RelapsedRefractory Multiple Myeloma
Sponsor:
Ashraf Badros
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
1454GCC Phase III Anti-PD-1 MK-3475 and IMiD Pomalidomide Combination Immunotherapy in RelapsedRefractory Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to the inclusion of an IMid in combination with pembrolizumab Study Sponsor terminated the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label trial of Anti PD1MD-3475 Pomalidomide and dexamethasone The study will use standard FDA approved doses for both pomalidomide and dexamethasone The experimental drug Anti PD-1 MK 3475 given on days 1 and 14
Detailed Description:
This phase III study is focused on patients with relapsed or refractory multiple myeloma MK-3475 will be given as an intravenous infusion at every 2 weeks Treatment will be administered on an outpatient basis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None